ProPharma Group (PPG), a portfolio company of Odyssey Investment Partners, announces the expansion of the senior leadership team to include Bryan Katz as the new Chief Strategy Officer (CSO) / Head of Corporate Development.
CHICAGO, Sept. 13, 2022 /PRNewswire-PRWeb/ -- With over 20 years of proven and progressive leadership experience within the biopharma and life science industry, Bryan joins ProPharma Group from Syneos Health, where he served most recently as Senior Vice President, Global Head Solution Development. During his tenure at Syneos Health, Bryan led new product innovation across emerging biopharma and biotech segments, focusing on the design, incubation, and introduction of new solutions that enhance the viability and accessibility of novel therapeutics. A U.S. Marine, Bryan received his MBA from the Kellogg School of Management at Northwestern University, where he also earned his BS in Chemical Engineering, specializing in process dynamics and control. Bryan's in-depth experience is invaluable to delivering ProPharma Group's mission and higher purpose to improve patient health and safety.
In addition to Bryan's role of Chief Strategy Officer, he will be responsible for Corporate Development, where he will lead ProPharma Group's M&A strategy. Joining PPG at a period of great organic momentum, Bryan will align the strategic business and investment priorities of the company to accelerate ProPharma Group's growth initiatives.
"We are thrilled to welcome Bryan Katz as our new Chief Strategy Officer and Head of Corporate Development," said Michael Stomberg, ProPharma Group's CEO. "Bryan's expertise will enable ProPharma Group to further accelerate our growth strategy both organically and through acquisition. Bryan's extensive knowledge and technical expertise within the life sciences industry will provide an invaluable advantage as we explore strategic opportunities at all levels of the organization."
"I'm excited to join ProPharma Group and bring a fresh perspective to the company's strategic vision," said Bryan Katz. "The go-to-market strategy for global CROs is continuously evolving and ProPharma Group has a tremendous opportunity to explore new avenues of capitalizing on our competitive advantages and innovative solutions. I'm looking forward to working with ProPharma Group's talented leadership team to drive initiatives rooted in their unique strategic vision of continued and sustainable growth."
About ProPharma Group
ProPharma Group is the global, independent, single-source provider of regulatory, clinical and compliance services serving pharmaceutical, biotechnology, and medical device companies. Founded in 2001, ProPharma Group has more than 2500 colleagues worldwide providing solutions to complex challenges in a dynamic regulatory environment. With the mission to improve the health and safety of patients, ProPharma Group is focused on delivering the highest quality services throughout the full product lifecycle including regulatory sciences, clinical research solutions, life science consulting, pharmacovigilance, and medical information services. For more information, please visit http://www.propharmagroup.com.
About Odyssey Investment Partners
Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit http://www.odysseyinvestment.com.
Media Contact
Barb Turney, ProPharma Group, 4066004495, [email protected]
SOURCE ProPharma Group
Share this article